SolarWinds Corp (SWI)

Return on equity (ROE)

Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Net income (ttm) US$ in thousands 111,903 38,657 22,915 12,071 -9,109 -18,944 -307,991 -930,375 -929,413 -942,647 -659,407 -48,907 -51,408 104,950 126,431 150,900 158,475 38,985 30,876 15,912
Total stockholders’ equity US$ in thousands 1,400,710 1,364,360 1,305,310 1,285,120 1,442,040 1,394,950 1,398,660 1,385,800 1,369,650 1,300,460 1,617,810 2,277,380 2,287,900 2,322,500 2,971,710 2,950,170 3,010,690 2,782,430 2,685,710 2,632,360
ROE 7.99% 2.83% 1.76% 0.94% -0.63% -1.36% -22.02% -67.14% -67.86% -72.49% -40.76% -2.15% -2.25% 4.52% 4.25% 5.11% 5.26% 1.40% 1.15% 0.60%

December 31, 2024 calculation

ROE = Net income (ttm) ÷ Total stockholders’ equity
= $111,903K ÷ $1,400,710K
= 7.99%

SolarWinds Corp's return on equity (ROE) has shown fluctuations over the period from March 31, 2020, to December 31, 2024. The ROE started at a relatively low level of 0.60% in March 2020, gradually increasing to 5.26% by December 2020. However, there was a dip in ROE to -2.25% by the end of December 2021.

The negative trend continued throughout 2022 and 2023, with ROE values persistently below zero and reaching as low as -72.49% in September 2022. The company experienced significant challenges during this period, reflected in the deteriorating ROE.

From March 31, 2024, the ROE started to improve, turning positive again at 0.94% and steadily increasing to 7.99% by the end of December 2024. This upward trend indicates a recovery in the company's profitability and efficiency in generating returns for its shareholders.

Overall, the analysis of SolarWinds Corp's ROE over the specified period highlights both periods of strong performance and challenges, with the company showing resilience and the ability to recover from setbacks to deliver positive returns for its equity holders.